Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Raia DrogasilBSP:RADL3 +5.87%94 Debt-to-EBITDA is 2.20 as of Mar. 2026, which is 2% below its 10-year median of 2.24. GuruFocus rates BSP:RADL3 with a GF Score™ of 94/100 and a GF Value™ of R$30.11 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 477 Healthcare Providers & Services companies, Raia Drogasil ranks better than 52.2% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Raia Drogasil's Debt-to-EBITDA or its related term are showing as below:
BSP:RADL3'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.45 Med: 2.24 Max: 2.57
Current: 2.12
During the past 13 years, the highest Debt-to-EBITDA Ratio of Raia Drogasil was 2.57. The lowest was 0.45. And the median was 2.24.
BSP:RADL3's Debt-to-EBITDA is ranked better than 52.2% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 2.19
vs BSP:RADL3: 2.12
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Raia Drogasil Debt-to-EBITDA Related Terms
Raia Drogasil Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Raia Drogasil's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Raia Drogasil's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Raia Drogasil Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Raia Drogasil's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Raia Drogasil's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Raia Drogasil (BSP:RADL3) has a Debt-to-EBITDA of 2.20 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Raia Drogasil. This is near median its historical median of 2.24. Over the past decade, Raia Drogasil's Debt-to-EBITDA has ranged from 0.45 to 2.57. According to the industry distribution chart, Raia Drogasil ranks #228 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 47.8%.
Is Raia Drogasil's Debt-to-EBITDA too high?
Raia Drogasil's current Debt-to-EBITDA of 2.20 is near median its 10-year median of 2.24. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 2.57. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.19. Raia Drogasil's value of 2.20 is 0.5% above this industry median. Based on the distribution chart, Raia Drogasil ranks #228 out of 477 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Raia Drogasil has a GF Score™ of 94/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Raia Drogasil's Debt-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Raia Drogasil ranks #228 out of 477 companies for Debt-to-EBITDA. This puts Raia Drogasil in the upper half of its industry. The industry median Debt-to-EBITDA is 2.19. Raia Drogasil's value of 2.20 is 0.5% above this benchmark. Historically, Raia Drogasil's own Debt-to-EBITDA has ranged from 0.45 to 2.57 over the past decade. While the company's 10-year median is 2.24 vs. the industry median of 2.19, Raia Drogasil has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Raia Drogasil's current Debt-to-EBITDA of 2.20 is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Raia Drogasil. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Raia Drogasil's current Debt-to-EBITDA is 2.20, which is near median its own 10-year median of 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raia Drogasil stock overvalued right now?
Based on GuruFocus' analysis, Raia Drogasil (BSP:RADL3) is currently considered Significantly Undervalued. The stock's GF Value™ is R$30.11, compared to a current price of R$20.55 — trading 31.8% below its estimated fair value. The current Debt-to-EBITDA is 2.20, which is near median its 10-year median of 2.24 and 0.5% above the Healthcare Providers & Services industry median of 2.19. Raia Drogasil's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Raia Drogasil (BSP:RADL3), the current Debt-to-EBITDA is 2.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Raia Drogasil (BSP:RADL3) Overvalued in 2026?
Based on GuruFocus' analysis, Raia Drogasil stock appears to be undervalued.
The current stock price of R$20.55 is trading 31.8% below its estimated GF Value™ of R$30.11.
GuruFocus considers Raia Drogasil to be Significantly Undervalued.
Key valuation signals for BSP:RADL3:
Debt-to-EBITDA: 2.20 (near median its 10-year median of 2.24)
GF Value™: R$30.11 vs. price of R$20.55 (31.8% below fair value)
Industry Position: 0.5% above the Healthcare Providers & Services median (#228 of 477)
No single metric tells the full story. See the BSP:RADL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Raia Drogasil SA operates a chain of pharmacies in Brazil. The company is mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics, dermocosmetics, and specialty medicines. Its pharmacies mainly operate under the Drogasil and Raia brands.
94GF Score
Get the complete analysis for BSP:RADL3
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:RADL3 has been successfully added to your 
